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Abstract
Background: Elite non-progressors (plasma viral load <50 copies/ml while antiretroviral naive)
constitute a tiny fraction of HIV-infected individuals. After 12 years follow-up of a cohort of 13
long-term non-progressors (LTNP) identified from 135 individuals with transfusion-acquired HIV
infection, 5 remained LTNP after 23 to 26 years infection, but only 3 retained elite LTNP status.
We examined the mechanisms that differentiated delayed progressors from LTNP in this cohort.
Results: A survival advantage was conferred on 12 of 13 subjects, who had at least one host
genetic factor (HLA, chemokine receptor or TLR polymorphisms) or viral attenuating factor
(defective  nef) associated with slow progression. However, antiviral immune responses
differentiated the course of disease into and beyond the second decade of infection. A stable p24-
specific proliferative response was associated with control of viraemia and retention of non-
progressor status, but this p24 response was absent or declined in viraemic subjects. Strong Gag-
dominant cytotoxic T lymphocyte (CTL) responses were identified in most LTNP, or Pol
dominant-CTL in those with nef-defective HIV infection. CTL were associated with control of
viraemia when combined with p24 proliferative responses. However, CTL did not prevent late
disease progression. Individuals with sustained viral suppression had CTL recognising numerous
Gag epitopes, while strong but restricted responses to one or two immunodominant epitopes was
effective for some time, but failed to contain viraemia over the course of this study. Viral escape
mutants at a HLA B27-restricted Gag-p24 epitope were detected in only 1 of 3 individuals, whereas
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declining or negative p24 proliferative responses occurred in all 3 concurrent with an increase in
viraemia.
Conclusion: Detectable viraemia at study entry was predictive of loss of LTNP status and/or
disease progression in 6 of 8, and differentiated slow progressors from elite LTNP who retained
potent virological control. Sustained immunological suppression of viraemia was independently
associated with preserved p24 proliferative responses, regardless of the strength and breadth of
the CTL response. A decline in this protective p24 response preceded or correlated with loss of
non-progressor status and/or signs of disease progression.
Background
A cohort of blood product recipients with transfusion-
acquired HIV (TAHIV) infected between 1981 and 1984
was followed prospectively by the Australian Red Cross
Blood Service HIV Lookback Team since 1987. There are
individuals in this cohort who have remained asympto-
matic for 27 years since infection without antiretroviral
therapy; some maintaining plasma HIV RNA levels to
below detectable levels and a stable CD4 T cell count, thus
retaining elite non-progressor status. Early natural history
studies on this and other cohorts suggested that TAHIV
infection may result in a shorter time to AIDS than sexu-
ally-acquired (SA) HIV infection [1,2]. This observed
increase in the rate of disease progression in TAHIV may
be due to the higher inoculation volume of blood product
compared with the much smaller blood or genital fluid
exchange involved in SAHIV infection [1], as well as the
known immunomodulatory effect of transfusion on
immune function [3,4]. Age is also an independent pre-
dictor for an increased rate of HIV disease progression
[5,6]. The bias toward an aged population requiring trans-
fusion is part of the composite disadvantage of transfu-
sion as a route of HIV infection [1]. In addition to HIV
infection, survival may be influenced by the underlying
medical cause for transfusion. Yet despite these disadvan-
tages, we previously observed a high frequency of non-
progression in this TAHIV cohort after 20 years of infec-
tion [7].
Early studies on this cohort of TAHIV patients led to the
identification of the Sydney Blood Bank Cohort (SBBC) of
long-term survivors [8], and that an attenuated nef-deleted
strain of HIV-1, transmitted from a single donor resulted
in slow to non-progression in these individuals [9]. How-
ever, after prolonged infection, not all SBBC members
maintained non-progressive disease [10-13]. Although
HLA type did not explain non-progression in this group
[14], we have observed differences in CD8 T cell responses
that are associated with HLA-dependent epitope recogni-
tion [15], and we have detected increased preservation of
helper T cell responses in non-progressors from this
cohort [16,17]. In addition to the well described host
genetic factors which may prolong non-progression [7],
recent studies have suggested an influence from innate
immune mechanisms, including polymorphisms that
decrease TLR function thereby reducing immune activa-
tion upon exposure to infections diseases [18], or the
FcγRIIA polymorphism (R/R) which is strongly associated
with progressive HIV disease as a result of impaired elim-
ination of HIV immune complexes [19].
While host genetic factors may predispose an individual
for delayed disease progression, there is substantial evi-
dence that antiviral T cell responses are required to sustain
non-progressor status. Earlier studies have demonstrated
an important role for Gag-specific CTL in delaying disease
progression [20,21]. Non-progressors that control virae-
mia in the absence of antiviral therapy also have strong
CD4 T cell proliferative responses to the Gag protein p24
[22]. Importantly, for Gag CTL to be efficient in killing
HIV-infected cells and therefore protective in controlling
viraemia, these must also be accompanied by p24-specific
T cell proliferative responses [23-25]. Appropriate T cell
help is also required to achieve maturation and display of
effector phenotypes on CTL associated with effective viro-
logical control [26].
To determine how these host genetic and immune factors
combined to contribute to prolonged non-progression in
our TAHIV cohort, we report here on the current status of
the elite non-progressors not on antiretroviral therapy
(ART), examining the factors that have influenced disease
in the former non-progressors (now on therapy or
deceased), and analyse potential mechanisms that have
influenced non-progression in this cohort for up to 27
years.
Materials and methods
Definitions of non-progression and disease progression
When this prospective study began in 1994, 13 LTNP were
identified in the NSW TAHIV cohort according to the orig-
inal guidelines for classifying LTNP: at least 10 years infec-
tion, stable CD4 T cell counts >500 cells/μl, and no
history of ART [27,28]. Subsequently, loss of LTNP status
was defined by any of the following events: a consistent
decline in CD4 T cell counts below 500/μl, commence-
ment of ART, and after viral load testing became routine,
plasma viraemia >5000 copies/ml. Elite non-progressorsRetrovirology 2008, 5:112 http://www.retrovirology.com/content/5/1/112
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were also defined by viraemia suppressed to <50 copies/
ml in addition to the above criteria. Disease progression
was defined by a CD4 T cell count of <200 and/or plasma
viraemia >100,000 copies/ml.
Patient details
The two non-progressor groups in this study included the
SBBC, consisting of 6 recipients of HIV-infected blood
from a common donor, and the other (Cohort 2) consist-
ing of 7 recipients infected by blood from different
donors. Clinical data from these LTNP were collected pro-
spectively since the late 1980s. T cell counts and viral load
tests were performed as part of routine clinical care. Blood
samples and clinical histories were provided after
informed consent was granted in accordance with guide-
lines from the ARCBS institutional Human Research Eth-
ics Committee.
T cell functional analyses
Anti-HIV T cell function assays were performed as previ-
ously described [15,29]. Briefly, the proliferative response
to HIV-1 p24 was determined by 6 day culture of PBMC
(1 × 105 cells/well) in RPMI medium with 15% pooled
human serum in round bottom microtitre plates, with 2
μg/ml HIV-1SF2 p24 (Chiron, Emeryville, CA, USA), or
medium alone for control. After 6 days, proliferative
responses were determined by 3H-thymidine incorpora-
tion during a further 6 hours culture, followed by cell har-
vest and reading in a liquid scintillation counter. Results
were expressed as stimulation index (SI; mean counts
antigen wells/mean counts control wells), and a SI >3 was
considered a positive response.
The response of CD8+ T cells to HIV antigen was meas-
ured by IFNγ ELISPOT, using pre-coated ELISPOT kits
according to the manufacture's protocol (Mabtech, Mos-
man, Australia). Firstly, the response to whole HIV pro-
teins was determined in response to antigen presented by
autologous B lymphoblastoid cell lines infected for 18
hours with 5 pfu/cell recombinant Vaccinia expressing the
HIV-1IIIB env,  gag,  pol, or nef  genes (Therion Biologics,
Cambridge, MA, USA), or E. coli lacZ as a control. Gag
responses were further characterised using overlapping
Gag peptides, firstly using a matrix of peptide pools, and
then individual peptides for confirmation (full Gag pep-
tide set; kindly provided by the NIH AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID,
NIH).
Provirus sequencing
DNA from PBMC was isolated using a QIAamp DNA mini
kit (Qiagen, Valencia, CA) according to the manufac-
turer's protocol. A nested polymerase chain reaction
(PCR) was used to amplify ~1.5 kb of the HIV gag gene
using the following primers:
5'-TCTCGACGCAGGACTCGGCTTGCTGA-3' (outer, sens
e),
5'-TACTGTATCATCTGCTCCTGTAT-3' (outer, antisense),
5_-GACAAGGAACTGTATCCTTTAGCTTC-3 (inner, sens
e),
And 5'-TCTGCTCCTGTATCTAATAGAGCTT-3' (inner,
antisense).
Both primary and secondary PCR reactions contained 2
units of Taq DNA polymerase (Promega, Madison, WI),
1× PCR buffer (Promega: 1 mM Tris- HCl, 5 mM KCl,
0.1% Triton X-100), 2.5 mM MgCl2, 200 nM of each
dNTP, and 0.4 nM of each primer in a total volume of 50
ul. Thermocycling conditions were as follows: 95°C for 2
min and then 35 cycles of 94°C for 30 s, 55°C for 30 s,
72°C for 2 min and a final a single cycle of 72°C for 7
min.
RNA was isolated from plasma using the QIAamp Viral
RNA Mini Kit (Qiagen, Valencia, CA) according to the
manufacturer's protocol. Gag gene was amplified using
the QIAGEN OneStep RT-PCR Kit using the outer primer
pairs mentioned above. Second round PCR reactions were
performed using the inner primer pair under the same
conditions.
PCR products were purified using a Millipore PCR purifi-
cation plate (Millipore, Billerica, MA, USA) and
sequenced by the ABI PRISM BigDye Terminator V3.1
Ready Reaction Cycle Sequencing kit (Applied Biosys-
tems, Foster City, CA, USA) on an ABI 377 automated
sequencer. Multiple sequences derived from each patient
were analysed using Sequencher 3.11 software (Gene
Codes Corp., Ann Arbor, MI, USA). Chromatograms
derived from both forward and reverse primers were
aligned with the reference strain HIV-1 HXB2.
Host genetic typing
Methods for HLA and chemokine receptor polymor-
phisms [30] and toll-like receptor (TLR) and FcγRIIA pol-
ymorphisms [31-33] have been described elsewhere.
Statistical analysis
The Fishers Exact test was used to associate genetic and
immune factors with viraemia and non-progressor status.
Results
Status of the non-progressor cohort
From all reported TAHIV cases from the state of NSW,
Australia, a cohort of 13 (10%) remained asymptomatic
after 10 years of infection. We now report that only 5
remain non-progressors after 23 to 26 years of HIV-1Retrovirology 2008, 5:112 http://www.retrovirology.com/content/5/1/112
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infection. Infection and treatment history for each subject
is summarised in Additional file 1. Most of these individ-
uals had a survival advantage, with 7 of 13 having at least
one host genetic polymorphism associated with slow pro-
gression, and 6 of 13 were infected with the SBBC nef-
defective HIV-1 strain [12], and combined, 12 of 13 had
at least one host or viral factor favouring slow progression.
Acting in opposition to these survival advantages, 5 of 8
former non-progressors had the FcγRIIA polymorphism
(R/R). While this genotype was absent in current LTNP,
the effect of the R/R genotype in promoting disease pro-
gression was not significant in this small study of 13 indi-
viduals. On balance, these competing survival factors
along with antiviral immune responses enabled a non-
progressive disease course to be established early in infec-
tion.
The loss of non-progressor status was based on increasing
viraemia and/or decreasing CD4 counts in 5 of 8, and ini-
tiation of ART in these individuals (Additional file 1).
Patient C122 lost LTNP status due to gradually increasing
viraemia, but died from unrelated causes before substan-
tial T cell loss was observed. Another two elderly individ-
uals (C18 and C54; both SBBC members), each with low
detectable viraemia, died before losing their non-progres-
sor status [13,17].
Antiviral immune responses associated with non-
progression
Host and viral genetic factors may have played a role in
delaying disease progression into the second decade of
infection in these 13 individuals, but this study also dem-
onstrates the importance of host immune responses in
sustaining this non-progressive disease course into and
beyond the second decade of infection. Immune status
and activity of HIV-specific CD4 T cells (proliferation)
and CD8 T cells (IFN-γ response) is shown for the current
non-progressors (Figure 1) compared with those that lost
their non-progressor status or died (Figure 2).
Antiviral CTL responses were variable during the second
decade of HIV infection, and did not always correlate with
viremia for members of these cohorts. Strong Gag-specific
CTL were detected in the Cohort 2 non-progressors (C13,
C53, C122, and C105 before ART), but the predominant
CTL response in the SBBC members was against Pol anti-
gens. These CTL appeared to be equally effective in con-
taining viral replication, whether Gag-specific as
demonstrated in earlier time points in C122, or Pol-spe-
cific in C18 (Figure 2).
The main factor that differentiated LTNP from those that
lost non-progressor status, was low or undetectable HIV
viraemia (<100 copies/ml; p = 0.021), and low viraemia
was associated with detectable p24 proliferative responses
(p = 0.0047). Loss of non-progressor status was strongly
associated with undetectable or declining p24 responses
(p = 0.0047). The combination of detectable p24 prolifer-
ative responses and strong (>500 SFC/106 PBMC) Gag
CTL responses was associated with low (<100 copies/ml)
or undetectable viraemia (p = 0.032).
Illustrating the importance of these combined Gag-spe-
cific T cell responses over time, low viraemia was intermit-
tently detected at earlier time points in C122, with sharp
increases in Gag CTL temporally associated with control
of transient viraemia at 17 years post infection. However,
Gag CTL later failed to contain viraemia in C122 beyond
approximately 20 years, coinciding with weakening pro-
liferative responses that gradually became negative. A sim-
ilar correlation between anti viral immune responses and
a spike in viral replication was demonstrated in SBBC
member C18, shown in more detail in Figure 3. Over the
course of 12 months, in response to an increase in virae-
mia peaking at 3600 copies/ml, the p24 proliferative
response increased, along with substantial expansions of
Pol-specific CTL in both precursor [15] and effector CTL
populations. The durability of immune control in this
individual was not determined as he died soon after from
causes unrelated to HIV disease, aged 83.
A decline in Gag-specific T cell responses preceding detect-
able viraemia was demonstrated in C13. This decline up
to year 16 was followed by a period of low detectable
viraemia (50 – 100 copies/ml) between years 19 – 22. A
rebound in these Gag-specific T cell responses coincided
with the first detectable viraemia at 19 years. These T cell
responses may have helped contain viraemia to low levels
over the following two years, but the sharp increase in
viral RNA at 22.7 years (Figure 1) coincided with a decline
in Gag-specific CD4 and CD8 T cell responses, whereas
Pol-specific CTL increased in response to rising viraemia.
These examples demonstrate the influence of conserved
Gag-specific responses, particularly helper T cell
responses, in reduced viral replication and delayed disease
progression. While the decline in these responses pre-
ceded detectable viraemia in C13, sufficient patient speci-
mens were not available to allow this critical observation
to be made in others who progressed.
Breadth of the anti-Gag CTL response in non-progressors
To determine why strong Gag CTL may have contained
viral replication in some, but failed in others, we mapped
the breadth of the Gag CTL response over time in patients
with at least moderate CLT responses to whole Gag anti-
gens. Pools of overlapping 15-mer Gag peptides were used
to test sequential PBMC spanning the study period by
ELISPOT. The composition of each peptide pool, and
examples of responses to these are shown in Figures 4 and
5, indicating the relevant HLA-specific epitopes containedRetrovirology 2008, 5:112 http://www.retrovirology.com/content/5/1/112
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in peptides at the intersection of positive pools. Figure 4
demonstrates a broad strong response by C53's PBMC to
multiple immunodominant epitopes, contrasted in Figure
5 by the restricted response from C122 to only two immu-
nodominant epitopes. The sequential analysis revealed
relatively high stability in the repertoire of Gag responses
over the past 10 years in most subjects (Additional file 2).
Relevant epitopes at intersecting positive peptide pools
were then confirmed using individual peptides (Figure 6).
This data demonstrates that retention of broadly reactive
Gag CTL was associated with ongoing non-progression
(C49, C64, and C53), while restriction toward a narrow
CTL specificity was observed in patients that eventually
lost control of viraemia (C122 and possibly C13). The
SBBC non-progressors C49 and C64 had responses to sev-
eral Gag epitopes, and although Gag responses were mod-
erate to weak in C64, this needs to be viewed in the
context of Pol CTL dominance in the SBBC. A strong but
Immunovirological status of the surviving non-progressors, showing T cell counts; viral RNA copies/ml plasma (data generated  from the Roche Amplicore standard assay, limit of detection 400, and Ultrasensitive assay, limit of detection 50, plotted sepa- rately); T cell proliferative responses to recombinant HIV-1 p24 (stimulation index; significant responses >3, defined by the  broken line); and IFNγ responses (ELISPOT) by CTL against autologous BCL expressing HIV-1 antigens after infection with  recombinant vaccinia Figure 1
Immunovirological status of the surviving non-progressors, showing T cell counts; viral RNA copies/ml plasma (data generated 
from the Roche Amplicore standard assay, limit of detection 400, and Ultrasensitive assay, limit of detection 50, plotted sepa-
rately); T cell proliferative responses to recombinant HIV-1 p24 (stimulation index; significant responses >3, defined by the 
broken line); and IFNγ responses (ELISPOT) by CTL against autologous BCL expressing HIV-1 antigens after infection with 
recombinant vaccinia. *SBBC member.
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Immunovirological status of the former non-progressors (same parameters as in figure 1) Figure 2
Immunovirological status of the former non-progressors (same parameters as in figure 1). Initiation of antiretroviral 
therapy is defined by an arrow in the viral load panels. Other reasons for loss of non-progressor status are summarised in 
Additional file 1.
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restricted Gag response was also seen in C18, but these
Gag responses were likely to be secondary in controlling
viraemia, as suggested by the kinetics of Pol CTL in
response to a spike in viraemia (Figure 3). Pol CTL recog-
nition was confirmed by subsequent analysis of responses
to peptide pools derived from the full set of Pol overlap-
ping 15-mer peptides. Moderate to strong responses to
multiple pools containing epitopes in the reverse tran-
scriptase protein were detected in SBBC members C49,
C64, C18, C54, but weakly in C98 (data not shown). C18
also responded strongly to integrase peptides.
A strong but narrow CTL response may eventually fail to
control viral replication. Restricted recognition of only
one A3 and two B27 Gag epitopes in C13 appeared suffi-
cient to have contained viraemia for many years, but the
most recent viral load result (Figure 1) suggested that
immune escape from these B27-restricted CTL may have
occurred recently. Similarly, the predominant response by
C122 against an immunodominant B27 epitope (Figure 5
and 6) may have contained earlier spikes of increased
viraemia, but ultimately failed to contain increasing viral
replication in later years (Figure 2).
Limited immune escape from HLA B27-restricted CTL
To determine why immunodominant B27-restricted CTL
initially contributed to reduced viral replication in C13
and C122, but not in C117, sequencing of plasma and
PBMC derived virus spanning the period before and after
signs of disease progression was carried out to determine
if viral escape mutants had emerged in this region of Gag
(Figure 7). With the exception of one sample in 1996, a
well characterised escape mutant [34] was detected from
the earliest time point in C117. This escape mutant was
not detected in C13 or C122, and hence was not the cause
for the loss of control of viraemia in C122, nor was it
detected in the latest time point from C13 when viraemia
first increased above 1000 copies/ml. This suggests that
immune escape at this B27 Gag epitope was not a major
cause of disease progression in very long term infected
Dynamics of immune responses during an episode of increased viral replication in SBBC patient C18 Figure 3
Dynamics of immune responses during an episode of increased viral replication in SBBC patient C18.
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Identification of responses to Gag peptide epitopes by peptide pool mapping in a stable non-progressor (C53, 21.3 years post  infection) Figure 4
Identification of responses to Gag peptide epitopes by peptide pool mapping in a stable non-progressor (C53, 
21.3 years post infection). Mean INF-γ spots/106 PBMC (SFC), and representative ELISPOT images are shown. Individual 
peptides intersecting positive peptide pools containing HLA-relevant epitopes (Additional file 2) were then tested individually, 
and positive responses indicated by dark shaded cells, and dominant responses in large font.
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individuals. The sole common factor was a decline in p24-
specific proliferative responses.
Discussion
Non-progressors are considered to represent the tail end
of the distribution curve of rates of disease progression,
and although elite non-progressors are extending this
curve even further, disease progression may be inevitable
in this rare group of individuals. Recent analyses of the
SBBC may support this suggestion [13,17]. However,
death from other causes has prevented the establishment
of definitive proof of disease progression in some individ-
Identification of responses to Gag peptide epitopes by peptide pool mapping in an individual with increasing viraemia (C122,  20.3 years post infection) Figure 5
Identification of responses to Gag peptide epitopes by peptide pool mapping in an individual with increasing 
viraemia (C122, 20.3 years post infection). Mean INF-γ spots/106 PBMC (SFC), and representative ELISPOT images are 
shown. Individual peptides intersecting positive peptide pools containing HLA-relevant epitopes (Additional file 2) were then 
tested individually, and positive responses indicated by dark shaded cells, and dominant responses in large font.
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uals. Two SBBC subjects that did not consent to prospec-
tive analysis died from unrelated causes in 1987 and
1994, and the sole SBBC recipient on therapy (C98) has
since died from non-HIV causes. Two other elderly sub-
jects also died from non-HIV causes (C18 and C54), but
control of viraemia at low levels along with normal CD4
Breadth of Gag CTLs, showing responses to individual peptides selected from intersecting positive peptide pools, in non-pro- gressor C49 (A), C64 (B), C18 (C), C13 showing an early and late time point (D), C53 (E), and C122 (F) Figure 6
Breadth of Gag CTLs, showing responses to individual peptides selected from intersecting positive peptide pools, in non-pro-
gressor C49 (A), C64 (B), C18 (C), C13 showing an early and late time point (D), C53 (E), and C122 (F). Limit of detection 50 
spots/106 PBMC.
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T cell counts suggested there was no evidence for loss
LTNP status before death. This leaves the three elite non-
progressors from the SBBC described in this study, and
one is also advanced in age. One of the elderly Cohort 2
LTNP (with wild-type HIV infection) also died recently
from non-HIV causes aged 84 (C122). We may have an
opportunity to determine the factors involved in disease
progression in the other two Cohort 2 non-progressors
(C13 and C53). Both had very low but detectable virae-
mia, but a recent inversion of CD4 : CD8 T cell ratio in
C13 is evident of a change in HIV-induced immune acti-
vation. Based on the decline in the proliferative response
to p24 preceding this recent increase in viraemia, it is
likely that these together signify a transitionary stage
toward disease progression in C13.
The p24 proliferative response was the single immune
parameter that consistently defined control of viraemia
and non-progression. The p24 proliferative response may
also be specifically protective, as suggested by a study
showing that responses to some Pol antigens were associ-
ated with increased viraemia, whereas a protective associ-
ation was always found in responses to Gag antigens [35].
HIV-specific proliferative responses may also promote
CTL proliferation. This was supported by the response to
a spike in viraemia in patient C18, where the HIV-specific
CD4 and CD8 memory T cell pool increased and were
maintained throughout this period (both proliferation
and CTL precursor assays measure proliferating antigen-
specific memory T cells), whereas effector CTL (ELISPOT-
positive cells) peaked then declined as viraemia declined.
These data suggest that effective helper T cell function
involves proliferation followed by maturation into both
effector and costimulatory cells that provide "help" for
other lymphocyte functions. Thus, antigen-specific CD8 T
cell proliferation may be directly associated with CD4
proliferation to epitopes on the corresponding antigen. It
is also possible that loss of protective CD4 and CD8 HIV-
specific proliferation may be mediated by a common
immunological defect.
The other distinguishing feature of most slow and non-
progressor subjects that we have studied is the predomi-
nance of Gag CTL, but the SBBC non-progressors were
exceptional in having a Pol-dominant CTL response. This
observation is unexpected, considering the extensively
published role for Gag CTL in controlling viraemia
[20,21,23]. Also peculiar to SBBC members, the strongest
CTL responses were detected in those with detectable
viraemia, and were weaker in subjects with undetectable
viraemia [15]. In the non-attenuated HIV-infected non-
progressors, strong immunodominant CTL combined
with detectable proliferative responses to p24 appears to
have contributed to viraemia remaining <100 copies/ml
after 23 years HIV-1 infection in patient C53. The individ-
ual with the strongest CTL response was C122, but CTL
increased as viraemia increased in this patient, while pro-
liferative responses to Gag p24 declined. Given the pre-
dominant CTL response in this subject was directed
against an immunodominant HLA B27 restricted p24
Amino acid sequences of the HLA B27 restricted Gag epitope KRWIILGLNK) Figure 7
Amino acid sequences of the HLA B27 restricted Gag epitope KRWIILGLNK).
                                                                       260                                                                 272 
consensus clade B    E I Y K R W I I L G L N K 
C13 plasma 31/7/07    _  _  _  _  _  _  _  _  _  _ _  _  _ 
C117 plasma 22/3/95   D _  _  _ G  _  _  _  _  _ _  _  _ 
C117 plasma 26/6/96   _  _  _  _  _  _  _  _  _  _ _  _  _ 
C117 plasma 29/10/96  D _  _  _ G  _  _  _  _  _ _  _  _ 
C117 plasma 23/6/99   D _  _  _ G  _  _  _  _  _ _  _  _ 
C117 plasma 22/3/00   D _  _  _ G  _  _  _  _  _ _  _  _ 
C122 plasma 18/5/99   _  _  _  _  _  _  _  _  _  _ _  _  _ 
C122 plasma 3/5/04    _  _  _  _  _  _  _  _  _  _ _  _  _ 
C122 PBMC 3/5/04    _  _  _  _  _  _  _  _  _  _ _  _  _ Retrovirology 2008, 5:112 http://www.retrovirology.com/content/5/1/112
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epitope, and that there were no immune escape sequences
detected at this epitope, it is likely that the decline in the
p24-specific proliferative response was the key event that
contributed to the failure of CTL to control viraemia, as it
is understood that CTL have much reduced functional
efficiency in containing viraemia in the absence of helper
T cell responses [24]. Another study of HLA B57 positive
individuals found no association between disease pro-
gression and the strength of CTL responses or the emer-
gence of viral escape mutants at these epitopes, but it was
found that viral replicative fitness influenced disease
course [36]. The contribution of p24-specific proliferative
responses was not investigated in that study.
The neutralising antibody (NAb) response is another
immune mechanism that may contribute to long term
control of viraemia [37]. We recently analysed viral repli-
cative fitness and the strength of NAb responses, and con-
firmed that NAb titres in long-term infected subjects were
inversely proportional to viral load. However, NAb titres
in SBBC members were comparatively weaker, and in par-
allel with CTL responses, were highest in those with
detectable viraemia. The presence of strong Nabs did not
prevent some SBBC members from developing signs of
disease progression [38]. Hence, we suggest that while
broad Nabs might be generated due to a crippled infection
they do not prevent disease progression, particularly in
the absence of antiviral helper T cell responses.
What is the key factor that sustains a non-progressive dis-
ease course, and what initiates the decline in protective
immunity after many years of a non-progressive disease
course. Could a change in viral pathogenicity overcome
this delicate balance between host and virus, or could pro-
gressive weakening of the CD4 T cell response by slow
virus turnover gradually allow the virus to escape the com-
bined effector mechanisms of the HIV-specific cell-medi-
ated and humoral immune responses? Escape mutants at
the B27 epitope KRWIILGLNK have been observed under
conditions of high viral load and evolutionary drift [34],
which was likely in C117, but not for both C13 and C122,
who had prolonged periods of immune control in the
presence of p24 proliferative responses, and very low
viraemia up to or beyond the second decade of HIV infec-
tion. Disease progression in one SBBC member (C98) and
the SBBC infecting donor was associated with the emer-
gence of divergent strains which preceded viral load
increases and subsequent changes in immune responses
[39,40]. Also, these individuals lacked protective p24 pro-
liferative responses and had detectable viraemia before
viral divergence occurred, providing further evidence that
effective immune control over viral replication to levels
below a putative threshold, may prevent the emergence of
escape mutants or fitter variants. Therefore, the common
factor in all these observations is the decline or lack of p24
proliferative responses, suggesting that a lack of helper T
cell responses may result in a reduced capacity to contain
viral replication by other immune effector responses
including CTL, independent of the presence of viral
escape mutants.
Conclusion
Our studies have demonstrated that host and viral genetic
factors can contribute to delayed disease progression, but
the single immunological factor that functionally defined
non-progression was Gag-specific CD4 T cell prolifera-
tion. The maintenance of this p24-specific response does
not require detectable viral replication for antigenic stim-
ulation [41]. Detectable p24-specific T cell proliferation
defines the immunocompetent recall response to viral
antigen, and when spikes of viral replication were
detected in these individuals, these cells likely provided T
cell help for maintaining functional antiviral effector
responses by other CD4 and CD8 T cells, including non-
cytolytic antiviral mechanisms [41], and may also provide
T cell help for efficient generation of NAb by HIV-specific
B cells. We have demonstrated that a decline in this pro-
tective p24 response in slow progressors either preceded
or coincided with classic signs of disease progression.
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